Evaluating the Impact of Unmeasured Confounding with Internal Validation Data: An Example Cost Evaluation in Type 2 Diabetes
Authors:
- Douglas FariesDFDouglas Faries
- Xiaomei PengXPXiaomei Peng
- Manjiri PawaskarMPManjiri Pawaskar
- Karen PriceKPKaren Price
- James D. StameyJSJames D. Stamey
- John W. SeamanJSJohn W. Seaman
- 1 March 2013
- journal article
- Published by Elsevier in Value in Health
- Vol. 16 (2) , 259-266
Abstract
No abstract availableKeywords
This publication has 28 references indexed in Scilit:
- Probabilistic Approaches to Better Quantifying the Results of Epidemiologic StudiesInternational Journal of Environmental Research and Public Health, 2010
- Observational Research, Randomised Trials, and Two Views of Medical SciencePLOS Medicine, 2008
- Studying Prescription Drug Use and Outcomes With Medicaid Claims DataMedical Care, 2007
- Estimating Treatment Effects Using Observational DataJAMA, 2007
- Sensitivity analysis and external adjustment for unmeasured confounders in epidemiologic database studies of therapeuticsPharmacoepidemiology and Drug Safety, 2006
- A Checklist for Retrospective Database Studies—Report of the ISPOR Task Force on Retrospective DatabasesValue in Health, 2003
- Randomized, Controlled Trials, Observational Studies, and the Hierarchy of Research DesignsNew England Journal of Medicine, 2000
- A Comparison of Observational Studies and Randomized, Controlled TrialsNew England Journal of Medicine, 2000
- Propensity score methods for bias reduction in the comparison of a treatment to a non-randomized control groupStatistics in Medicine, 1998
- Reducing Bias in Observational Studies Using Subclassification on the Propensity ScoreJournal of the American Statistical Association, 1984